Search results
What’s keeping the U.S. from allowing better sunscreens?
Daily Montanan via Yahoo News· 7 days agoWhen dermatologist Adewole “Ade” Adamson sees people spritzing sunscreen as if it’s cologne at the...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 1 day agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Morningstar· 5 days agoModerna and Merck said they saw positive results from a Phase 2b study evaluating mRNA-4157 in combination with Keytruda in patients with high-risk skin cancer that was surgically removed. With ...
Playbux Rolls Out Two New Upgrades to Make its Ecosystem More Universal and Rewarding
Digital Journal· 5 days ago...Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June...
Promising HPV Cancer Treatment Advances in Clinical Trial By Investing.com
Investing.com· 4 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has reported...
Replimune (REPL) Gains on Positive Data From Melanoma Study
Zacks· 1 day agoFree Report) announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ (BMY Quick QuoteBMY - Free Report ...
Molecular Templates reports progress in cancer therapy trials By Investing.com
Investing.com· 5 days agoMolecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company, has announced...
UnitedCFX.com - Trusted Partner in Automated AI Trading
Digital Journal· 5 days ago...Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga· 5 days agoMonday, Moderna Inc MRNA and Merck & Co Inc MRK announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating ...
DermaSensor COO on bringing skin cancer detection device to market - South Florida Business Journal
The Business Journals· 3 days agoAfter years of development, DermaSensor's handheld skin cancer detection tool is now in the hands of...
